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LYSOSTAPHIN: AN ENZYMATIC APPROACH TO STAPHYLOCOCCAL DISEASE.
1. IN VITRO STUDIESS
Since 1960, Schindler and Schuhardt have reported several studies on a
unique substance which rapidly and specifically lyses staphylococci but has
no effect on bacteria of other genera.`' This agent, termed lysostaphin,
contains at least two enzymes, a peptidase and an N-acetyl-glucosamini-
dase.' The specific antistaphylococcal effect is thought to be due to the
peptidase which cleaves genus-specific polyglycine bridges in the staphylo-
coccal cell wall.' The enzyme can lyse heat-killed staphylococci and isolated
cell wall preparations as well as living microorganisms.' Thus it appeared
that lysostaphin might be active against metabolically quiescent staphylo-
cocci in abscess lesions where penicillin and other antimicrobials are
largely ineffective. This study describes the in vitro activity of lysostaphin.
The paper that follows evaluates its use as a therapeutic agent in experi-
mental staphylococcal infections.
METHODS
The following coagulase positive strains of Staphylococcus aureus isolated from
human sources were employed. Wild-Type Staphylococci: a) Giorgio strain.-
This strain was used as the standard test organism in the majority of experiments
and has been previously described.' This strain produces penicillinase and is inhibited
by 25 utg/ml. of penicillin G and 0.39 ,ug/ml. of oxacillin. b) Smith Compact
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variant.-This strain, which does not produce penicillinase and is inhibited by 0.016
,ug/ml. of penicillin G, has been described extensively."8 The Driver and 502A
staphylococcal strains also employed in these studies possess characteristics of "wild-
type" strains.9"0 Encapsulated Staphylococci: a) Smith Diffuse variant.-This strain
is mouse virulent (ip), possesses an antiphagocytic surface antigen, and grows
characteristically in streaming diffuse colonies in serum soft agar."' Two other
staphylococcal strains used in the present studies, the Welwood and Shiver strains
have similar characteristics.7"8
Stock cultures were maintained on agar slants stored at 40C., and 18 hour
transplants were made in trypticase soy broth. Bacteria in the exponential phase of
growth were grown on a shaker for five hours. Large populations of organisms were
obtained by concentrating liter volumes of shaker-grown cultures. Microorganisms
were washed once and resuspended to appropriate concentrations in Tris Buffer.
Lysostaphin-resistant staphylococci were isolated from survivors of enzyme-treated
cultures. These survivors were subjected to a series of tests designed to com-
pare them with the parent strain: 1) Tube coagulase and clumping factor ("slide
coagulase") assays were carried out using pooled human plasma.' 2) Phage typing
was performed by the Tennessee Department of Public Health, Division of Labora-
tories, Nashville, Tennessee. 3) Antibiotic sensitivities were determined using serial
twofold dilutions in trypticase soy broth.7 4) Two methods were employed to deter-
mine penicillinase production: (a) A modification of the rapid starch-iodide assay.'
Starch-iodide was prepared as 0.0013 NI8 in 0.005 M KI with 0.4% soluble starch.*
Organisms were scraped from an agar slant and resuspended in M/10 phosphate
buffer (pH 5.9) to give a cloudy suspension. To 1 ml. of this suspension was added
0.1 ml. penicillin G (2 mg/ml.) and 1 ml. starch-iodide solution. Decolorization
of the blue starch-iodide mixture indicated penicillinase production. (b) Modified
Gots test.' Trypticase soy agar plates containing a 1:100 dilution of a broth culture
of Sarcina lutea (inhibited by 0.005 ,ug/ml. of penicillin G) and 0.008 ,ug/ml. penicillin
G were poured and allowed to solidify. Eighteen-hour broth cultures of the strains
to be tested were streaked in a circle on the surface of the plates. Strains producing
penicillinase permitted a zone of satellite Sarcina colonies to appear. 5) Virulence
was tested by employing two mouse infections previously studied: '-" (a) Animals
were injected intraperitoneally with 0.4 ml. of an 18-hour culture in trypticase soy
broth. Mortality rates were determined at 24 hours. (b) 0.2 ml. of an 18-hour culture
was injected via a tail vein. Mice were observed for 28 days and cumulative mor-
tality rates recorded.
Lysostaphin* and Trypsin** were prepared in sterile 0.05M Tris buffer, pH 7.5,
which was 0.145M with respect to NaCl. The buffer was sterilized by Millipore
filtration (0.45u). The Chalaropsis B enzyme, a P-1, 4-N,O-diacetylmuramidase, used
in solubilizing the staphylococcal cell wall, was prepared as previously described.'
Lysostaphin activity was measured by determining killing curves using standard
pour plate techniques. Mixtures of enzyme and staphylococci in Tris buffer were
incubated in a water bath at 370C. Aliquots were removed at intervals, diluted ap-
propriately in 0.9% saline, and cultured in trypticase soy agar. As trypsin destroys
* Fisher Scientific Co.
* Lot number 142-123-1, kindly supplied by Dr. Peter Tavormina of the Mead
Johnson Research Center, Evansville, Indiana.
** C. E. Boehringer and Soehne, Manheim, Germany.
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lysostaphin activity,2 residual lysostaphin was inactivated by adding trypsin (0.1 to
0.5% final concentration) to the pour plates.
Human leukocytes were obtained by dextran sedimentation of whole blood as pre-
viously described.' Washed leukocytes were suspended in 10% human serum in
Hank's solution. Staphylococci were added in a ratio of one microorganism to one
polymorphonuclear leukocyte and these mixtures were rotated on a drum at 370C.
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FIG. 1. The effects of increasing concentrations of lysostaphin on the Giorgio
staphylococcus. The numbers in parentheses indicate the number of experiments in
each group.
The incorporation of labeled glycine* by lysostaphin-resistant staphylococci and
the subsequent fractionation of the microorganism were performed as previously
described.'6 Washed cells (12.8 mg. dry wt.) from the log phase of growth were
suspended in 20 ml. of synthetic media containing 2.0 uic of 14C-glycine. Samples
were incubated with shaking at 370C. and 5 ml. aliquots were withdrawn and frac-
tionated as described.'6
After solubilization of the cell wall with the Chalaropsis N-acetylmuramidase,
aliquots corresponding to 0.8 mg. dry weight cells were placed on a Sephadex G-25
column (1 x 25 cm.) and eluted with water. Fractions (0.7 ml.) were collected and
added to 10 ml. of scintillation fluid and counted.'
* Purchased from New England Nuclear Corporation as 14C-glycine, specific
activity 74 mc/mmole.
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RESULTS
In vitro activity of lysostaphin
Lysostaphin rapidly kills Staphylococcus aureus in zitro. As is demon-
strated in Figure 1, increasing doses of lysostaphin killed increasing num-
bers of staphylococci. Using 70 ,ug/ml. of lysostaphin, the bacterial popu-
lation fell approximately two log units in one hour. Ten times as much
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FIG. 2. The effects of lysostaphin or oxacillin on the Giorgio staphylococcus. This
microorganism is inhibited by 0.39 ,ug/ml. of oxacillin. The numbers in parentheses
indicate the number of experiments in each group.
lysostaphin reduced the viable count by five log units. Oxacillin, even in
amounts one thousand times as large (70,000 ,ug/ml.), did not alter the
population of a resting oxacillin-sensitive staphylococcal strain during this
time period (Fig. 2).
Temperatures between 220C. and 560C. had relatively little influence
on the speed of bacterial killing. At room temperature (220C.), initial
killing rates were less than those observed at 370C., but at the end of an
hour similar degrees of killing had occurred. At 560C. lysostaphin re-
mained actively lytic, but such temperatures alone killed staphylococci.
A number of staphylococcal strains have been described which produce
diffuse streaming colonies in serum or plasma soft agar, have increased
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virulence for mice, possess antiphagocytic surface antigens, and appear
encapsulated.68 Although only a few of these strains have been isolated
from patients with active staphylococcal infection,8 it has been proposed that
such strains represent the biological form of the disease-producing staphylo-
coccus in vivo and may actually be responsible for more disease than is
currently suspected."7 Studies were thus performed to determine whether
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FIG. 3. In vitro lysostaphin susceptibility of "wild-type" and encapsulated staphylo-
cocci. The upper curves show lysostaphin activity (35 ,ug/ml.) against the diffuse
encapsulated and the compact "wild-type" variants of the Smith strain of staphylo-
coccus. The lower curves show the range of lysostaphin activity (700 ug/ml.)
against several encapsulated (Diffuse, Welwood, and Shiver) and "wild-type"
(Compact, Driver, and 502A) staphylococcal strains.
the surface structures of such encapsulated strains would impair the action
of lysostaphin. As noted in Figure 3, this was not the case. Small quantities
of lysostaphin (35 jug/ml.) were more active against an encapsulated
strain than against a usual wild-type strain, while larger amounts of
lysostaphin lysed encapsulated and wild-type staphylococci at similar rates.
Studies performed both in experimental animals"8"9 and in vitro"' have
clearly demonstrated that bacteria which have reached maximal titers in
tissue or in the test tube are relatively insusceptible to penicillin despite
219YALE JOURNAL OF BIOLOGY AND MEDICINE
rapid killing of smaller numbers of these same bacteria during a phase of
active multiplication. As Figure 4 demonstrates, lysostaphin was active
against very large populations of staphylococci that were penicillin in-
susceptible. In this instance lysostaphin produced over a hundredfold
reduction in a large population of microorganisms when penicillin G showed
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FIG. 4. Comparison of penicillin G and lysostaphin activities against large popula-
tions of the Smith Compact staphylococcus. This strain does not produce penicillinase
and is inhibited by 0.016 ug/ml. of penicillin G.
no activity over the six-hour period of study even though over 4,000
times the standard minimum inhibitory concentration of the drug was
employed.
Lysostaphin was relatively stable at 370C. and maintained its activity
in human serum. Over a 36-day period of incubation at 370C. lysostaphin
was slowly inactivated (Fig. 5A), but the enzyme was still able to kill
more than 99% of the staphylococci in one hour. In a system containing
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50%o serum no alteration of lysostaphin activity could be detected (Fig.
5B).
Lysostaphin activity was only slowly reduced after repeated exposure to
staphylococci. As shown in Figure 6, the addition of fresh populations of
staphylococci at hourly intervals to buffer containing lysostaphin produced
some reduction in staphylococcal killing after each successive staphylococcal
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FIG. 5A. Effect of prolonged incubation at 37'C. on the activity of lysostaphin
(70 ug/mi.). The Giorgio staphylococcus was used as the test organism.
FIG. 5B. Effect of human serum on lysostaphin activity (35 ug/ml.) against the
Giorgio staphylococcus. Two separate experiments are represented in each group.
challenge. However, after three additions of fresh staphylococci, over 91%o
of the microorganisms were still killed during the fourth hour. The ac-
cumulation of inhibitory and toxic end products consequent to bacterial
lysis provides the most likely explanation for the observed progressive
decrease in lysostaphin activity. Lysostaphin controls incubated alone
maintained full activity for the duration of the experiment.
Effect of intracellular residence on lysostaphin activity
Coagulase-positive staphylococci are able to survive for a prolonged time
within polymorphonuclear leukocytes.2' Studies were thus undertaken to
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determine whether lysostaphin was active against such phagocytized
staphylococci. These studies are represented in Figure 7. When human
leukocytes were allowed to phagocytize the Giorgio staphylococcus (a
non-encapsulated strain) the intracellular population of staphylococci re-
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FIG. 6. Sustained lytic activity of lysostaphin (70 jug/ml.). The numbers refer
to successive additions of Giorgio staphylococci at hourly intervals. The dashed line
indicates the activity of lysostaphin incubated for 3 hours and exposed to staphylococci
during the fourth hour.
mained constant over the one-hour period of study. Lysostaphin (30
,ug/ml.) had no effect on such intracellular staphylococci, while staphylo-
cocci alone were rapidly killed on exposure to lysostaphin. The intracellular
position had protected the bacteria from lysostaphin action. Further-
more, if fresh leukocytes, extracellular staphylococci, and lysostaphin
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were simultaneously mixed together, rapid staphylococcal killing was
initially observed. As phagocytosis proceeded and more staphylococci were
ingested, killing slowed and then stopped.
In order to demonstrate that leukocytes did not inactivate the lysostaphin
and thus, account for the observed impairment in killing, leukocytes
8
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FIG. 7. The effects of lysostaphin (30 ug/ml.) on intracellular and extracellular
staphylococci. The Giorgio staphylococcus and human polymorphonuclear leukocytes
were employed.
were suspended in lysostaphin (35 jug/ml.) at 370C. for one hour. The
leukocytes were then removed by centrifugation, staphylococci were added
to the lysostaphin-containing supernate, and no impairment of lysostaphin
activity was observed.
Leukocytes that had been exposed to high concentrations of lysostaphin
(1,400 Ag/ml.) for 30 minutes at 370C. were twice washed in buffer and
homogenized in a teflon grinder. No evidence of lysostaphin activity was
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obtained in such leukocyte homogenates. This finding suggests that, in the
system described, lysostaphin did not enter leukocytes in appreciable
amounts or was promptly inactivated by intracellular residence.
In vitro resistance to lysostaphin
Lysostaphin-resistant microorganisms were easily recovered in vitro.
The Giorgio strain of Staphylococcus aureus was exposed to 3,500 jug/ml.
TABLE. 1. BIOLOGIC CHARACTERISTICS OF PARENT STAPHYLOCOCCUS AND
LYSOSTAPHIN-RESISTANT VARIANTS
Giorgio parent Variant no. 1 Variant no. 2
Morphology Yellow-white opaque Pearlytranslucent Pearlytranslucent
colony colony colony
Growth rate Normal Prolonged lag phase Prolonged lag phase
Phage type 47/53/54/75/77 47/53/54 47/54
Coagulase + + +
Clumping factor + + 0
Morphology in plasma Compact witha few Diffuse with occas- Compact with rare
soft agar diffuse colonies ional compactcolony diffusecolony
Mouse mortality ip 0/10 0/4 0/4
(Dead/Total)
Mouse mortality iv 17/20 (85%) 11/20 (55%) 19/23 (83%)
(Dead/Total)
Penicillin sensitivity 25 ,g/ml. 0.195 ,ug/ml. 1.56jg/ml.
Penicillinase production + + +
Lysostaphin sensitivity:
per cent staphylococci
killed in 1 hour
70,ug/ml. > 99.9 0 52
700 jug/ml. 0 >99
of lysostaphin at 370C. Aliquots were taken at intervals, plated without
trypsin, and the few surviving colonies were isolated. Two chosen at
random were studied further, as indicated in Table 1.
The colonial morphology of both variants differed from the parent
strain. They grew in pearly translucent colonies rather than in the yellow-
white opaque colony of the parent staphylococcus. The variants had a pro-
longed lag phase of growth as compared to the parent strain, although
identical titers were reached by 18 hours. Both variants and the parent
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strain were lysed by Group III phages; however, the variants were lysed
by fewer typing phages. Both variants produced tube coagulase. Variant
no. 1 produced primarily diffuse streaming colonies in plasma soft agar.
Variant no. 2 did not produce clumping factor ("bound coagulase").
Neither of the two variant strains were mouse virulent when injected
intraperitoneally. However, when mice were infected intravenously, the
parent strain and variant no. 2 produced equivalent mortality rates while
variant no. 1 killed significantly fewer mice (0.05 > p > 0.01).
While both lysostaphin-resistant variants and the parent strain pro-
duced penicillinase, the varients were significantly more sensitive to peni-
TABLE 2. INCORPORATION OF 14C-GLYCINE INTO LYSOSTAPHIN-RESISTANT
VARIANTS OF STAPHYLOCOCCUS AUREUS
Organism Time m,umoles 14C-glycine/mg. dry weight
(min) Protein Cellwall
Parent 10 56 120
20 105 315
30 160 530
Variant no. 1 10 37 30
20 66 71
30 123 129
Variant no. 2 10 45 106
20 90 258
30 158 436
cillin. The parent strain was sensitive to 70 jug/ml. of lysostaphin while
both variant strains were resistant to this quantity of lysostaphin. When
700 jig/ml. of lysostaphin was employed, variant no. 1 remained completely
resistant while variant no. 2 was sensitive to this quantity of enzyme.
Studies on the basis of lysostaphin resistance in Staphylococcus aureus.
The peptidase in lysostaphin releases N-terminal glycine and alanine,
thus cleaving the cross-linking polyglycine bridges which are unique to the
cell wall of Staphylococcus aureus.' Resistance to lysostaphin might result
from the absence of polyglycine structures in resistant variants or might
be due to the inaccessibility of susceptible bonds through an alteration in
the chemical or physical structure of the cell wall. The first possibility
was tested by determining whether 14C-glycine could be incorporated into
the cell wall. As shown in Table 2, both variant strains were able to
incorprate 14C-glycine into both cell wall and protein. Variant no. 2 incor-
225YALE JOURNAL OF BIOLOGY AND MIDICINE
porated glycine into both cell wall and protein at a rate similar to that
of the parent, whereas variant no. 1 incorporated considerably less label
into its cell wall than did the control. Nevertheless, both resistant variants
incorporated glycine into their cell wall structures and their insensitivity
to lysostaphin could not be ascribed to a lack of cell wall glycine.
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FIG. 8. Gel filtration of cell wall fractions of the parent Giorgio staphylococcus
and of two lysostaphin-resistant variants. The column was calibrated with dextran
blue which emerged in fractions 8-12 and dinitrophenyl-glycine which emerged in
fractions 18-26.
The cell wall fractions were further examined by subjecting them to
gel filtration on Sephadex G-25 to determine if the cell wall polymer
were cross-linked. The Chalaropsis B enzyme cleaves at every N-acetyl-
muramic acid and if polyglycine bridges were not cross-linked the resulting
disaccharide-peptide product would be eluted with low molecular-weight
materials. The results, shown in Figure 8, indicated that the product
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solubilized by the Chalaropsis B enzyme was still high molecular-weight
material. Though there were some products of low molecular weight in
variant No. 1, the resistance of these lysostaphin-resistant variants could not
be ascribed to a lack of cross-linking in the cell wall. The mechanism of
resistance is, therefore, more complex and possibly involves surface altera-
tions that protect susceptible bonds.
DISCUSSION
The present in z4tro studies confirm that lysostaphin is a potent bac-
teriocidal agent. It maintains its activity in human serum, is stable at body
temperature for long periods of time, and is capable of lysing repeated chal-
lenge inocula of staphylococci. Unlike penicillin it is active against large
populations of metabolically quiescent staphylococci analogous to those
found within staphylococcal abscesses. Thus lysostaphin would appear to
have potential therapeutic advantages in the management of staphylococcal
disease.
The finding that staphylococci residing within polymorphonuclear leuko-
cytes were protected from lysostaphin action resembled results of experi-
ments reported with penicillin. Tompsett has demonstrated that the activity
of penicillin is greatly diminshed against such intracellular staphylococci.'
Lysostaphin-resistant staphylococci were readily selected in vitro. How-
ever, they differed from the parent strain in several significant character-
istics. While the two variants did not change their phage type, ability to
produce coagulase, or mouse virulence when administered intraperitoneally,
their colonial morphology was markedly altered, their lag phase of growth
was greatly prolonged, and the variant most resistant to lysostaphin was
significantly less virulent for mice when given by the intravenous route.
The decreased mouse virulence resembles the situation reported with
laboratory produced penicillin-resistant staphylococci. These also appear
to have diminished disease-producing potential.' Furthermore, both
lysostaphin-resistant variants, while retaining their ability to produce
penicillinase, were found to be significantly more sensitive to penicillin
in vitro than was the parent staphylococcus. This suggests that the varients
either produced less penicillinase or that their cell wall structure was
altered so that they had become more susceptible to penicillin. If the latter
were correct these strains might have been killed before significant
quantities of penicillinase were produced.
The present studies suggest that resistance to lysostaphin is not related
to a basic change in the chemical composition of the staphylococcal cell
wall. The observed resistance to lysostaphin could not be attributed to the
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lack of glycine substrate or the absence of appropriate glycine cross-links
in the cell walls of the resistant variants. These findings suggest that
lysostaphin resistance may possibly relate to alterations in steric configura-
tions at the surface of the cell wall preventing the apposition of lysos-
taphin and the susceptible bonds in the wall.
Because of its potent activity in vitro, its selectivity, and its effect on
large populations of metabolically inactive staphylococci, it would appear
that lysostaphin deserves study as a therapeutic agent in experimental
staphylococcal infections.
SUMMARY
The in zvtro characteristics of lysostaphin, an enzyme that lyses the
cell walls of staphylococci, were studied. Unlike the penicillins, lysostaphin
rapidly killed large inocula of resting microorganisms. It maintained its
activity in serum and for prolonged periods at 370C. The enzyme was
equally active against encapsulated and non-encapsulated staphylococcal
strains. Like penicillin, lysostaphin was inactive against intracellular
staphylococci.
Lysostaphin-resistant staphylococci could be readily isolated in vitro.
These resistant variants differed from the parent strain in their colonial
morphology, slower growth rates, increased penicillin sensitivity, and,
in one instance, diminished virulence for mice.
Studies of lysostaphin-resistant staphylococci suggested that resistance
might possibly relate to configurational alterations on the surface of the
cell wall rather than to changes in its chemical composition.
The impressive in vitro activity of lysostaphin indicates that this enzyme
deserves further study as a therapeutic agent in experimental staphylo-
coccal infections.
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